Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

 

• Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world.
• Showed use of Dexcom G7 led to clinically and statistically significant reduction in HbA1c and improvement in quality of glucose control, including time in range and level 1 and 2 hyperglycemia.1
• Demonstrated additional clinically significant improvement in A1C reduction across study participants using Dexcom G7 in combination with various diabetes medications, including metformin, GLP-1s and SGLT2s.

https://www.businesswire.com/news/home/20260606323066/en/Dexcom-CONNECT-Study-The-Most-Significant-Clinical-Study-Demonstrating-CGM-Benefits-for-People-with-Type-2-Diabetes-Not-Using-Insulin